About Nordic Life Science Platform
The Nordic Life Science Platform (NLSP), with offices in Shanghai and Copenhagen, gives European Life Science companies a more safe, efficient, and easier access to the Chinese healthcare market by taking advantage of the preferential policies and opportunities at Hainan Boao Lecheng International Medical Tourism Pilot Zone (HBL) and Guangdong-Hong Kong-Macao Great Bay Area (GBA).
HBL and GBA offer special fast-track approval procedures for medical products and the opportunity to conduct Real-World data studies that can supplement the application for the NMPA registration which will speed up the approval process to sell in all of China.
NLSP is a one-stop service platform that delivers a Step-by-Step Market Entry Model that supports companies all the way from exploring, entering, and/or expanding in the Chinese healthcare market with the option to stop after each step of the process to determine their next step in China.
We match the demand for innovative medtech, healthtech, drugs, and rehabilitation equipment by the currently 25 hospitals at HBL and 45 designated hospitals in GBA with the supply of European life science companies for the benefit of Chinese patients, and that way help access and develop new sales/export opportunities in China.
Our experienced Team offers expert advice and supporting services such as project management, legal assistance, IPR protection, medical expert review, hospital matchmaking, contract negotiations, fast-track approval, CRO identification & selection, RWD Study implementation, NMPA filings, product registrations, market research, partner search, company set-up.
